JDRF T1D Fund
JDRF T1D Fund is a venture philanthropy organization dedicated to identifying and supporting early-stage commercial opportunities in Type 1 Diabetes research. By partnering with private capital, including venture capital, pharmaceutical companies, and other foundations, the fund aims to accelerate the development of treatments, preventions, and cures for T1D patients. With a focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, the fund prioritizes the most promising commercial opportunities in the field. Any profits generated are reinvested into new investments to advance the mission of finding a cure for Type 1 Diabetes.
SAb Biotherapeutics
Post in 2023
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.